These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 6224386)
41. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome. Sahin Y; Ayata D; Keleştimur F Eur J Endocrinol; 1997 Apr; 136(4):410-5. PubMed ID: 9150702 [TBL] [Abstract][Full Text] [Related]
42. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism. Villa P; Valle D; Mancini A; De Marinis L; Pavone V; Fulghesu AM; Mancuso S; Lanzone A Fertil Steril; 1999 Jan; 71(1):115-21. PubMed ID: 9935127 [TBL] [Abstract][Full Text] [Related]
43. Growth hormone and somatomedin-C secretion in patients with polycystic ovarian disease. Their relationships with hyperinsulinism and hyperandrogenism. Lanzone A; Fulghesu AM; Pappalardo S; Proto C; Le Donne M; Andreani CL; Muscatello R; Caruso A; Mancuso S Gynecol Obstet Invest; 1990; 29(2):149-53. PubMed ID: 2110544 [TBL] [Abstract][Full Text] [Related]
44. Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease. Mahabeer S; Jialal I; Norman RJ; Naidoo C; Reddi K; Joubert SM Horm Metab Res; 1989 Sep; 21(9):502-6. PubMed ID: 2684835 [TBL] [Abstract][Full Text] [Related]
45. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Robinson S; Henderson AD; Gelding SV; Kiddy D; Niththyananthan R; Bush A; Richmond W; Johnston DG; Franks S Clin Endocrinol (Oxf); 1996 Mar; 44(3):277-84. PubMed ID: 8729522 [TBL] [Abstract][Full Text] [Related]
46. Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. Ciotta L; De Leo V; Galvani F; La Marca A; Cianci A Hum Reprod; 1999 Dec; 14(12):2951-8. PubMed ID: 10601077 [TBL] [Abstract][Full Text] [Related]
47. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. Fulghesu AM; Angioni S; Portoghese E; Milano F; Batetta B; Paoletti AM; Melis GB Fertil Steril; 2006 Aug; 86(2):398-404. PubMed ID: 16769061 [TBL] [Abstract][Full Text] [Related]
48. Metabolic and androgen profile in underweight women with polycystic ovary syndrome. Anastasiou OE; Canbay A; Fuhrer D; Reger-Tan S Arch Gynecol Obstet; 2017 Aug; 296(2):363-371. PubMed ID: 28608050 [TBL] [Abstract][Full Text] [Related]
49. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Ciampelli M; Fulghesu AM; Cucinelli F; Pavone V; Caruso A; Mancuso S; Lanzone A Hum Reprod; 1997 Sep; 12(9):1897-901. PubMed ID: 9363702 [TBL] [Abstract][Full Text] [Related]
50. [Comparative diagnostic characteristics of carbohydrate metabolism disorders in women with polycystic ovary syndrome (PCOS)]. Orbetsova M; Orbetsova V; Kamenov Z; Kolarov G; Andreeva M; Genchev G; Zakharieva S; Borisov I Akush Ginekol (Sofiia); 2003; 42(4):10-5. PubMed ID: 14577361 [TBL] [Abstract][Full Text] [Related]
51. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Rajkhowa M; Bicknell J; Jones M; Clayton RN Fertil Steril; 1994 Apr; 61(4):605-12. PubMed ID: 8150099 [TBL] [Abstract][Full Text] [Related]
52. Type 2 diabetes and the polycystic ovary syndrome. Pelusi B; Gambineri A; Pasquali R Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409 [TBL] [Abstract][Full Text] [Related]
53. ACTH stimulation test in lean polycystic ovary syndrome patients with insulin resistance. Uncu G; Ozyurek SE; Uncu Y Fertil Steril; 2007 Sep; 88(3):670-4. PubMed ID: 17451692 [TBL] [Abstract][Full Text] [Related]
54. The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulinism. Lee PJ; Patel A; Hindmarsh PC; Mowat AP; Leonard JV Clin Endocrinol (Oxf); 1995 Jun; 42(6):601-6. PubMed ID: 7634500 [TBL] [Abstract][Full Text] [Related]
55. Glucose metabolism in obese and lean adolescents with polycystic ovary syndrome. Poomthavorn P; Chaya W; Mahachoklertwattana P; Sukprasert M; Weerakiet S J Pediatr Endocrinol Metab; 2013; 26(3-4):319-24. PubMed ID: 23314524 [TBL] [Abstract][Full Text] [Related]
56. Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia. Yildiz BO; Gedik O Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 100(1):62-6. PubMed ID: 11728659 [TBL] [Abstract][Full Text] [Related]
57. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Romualdi D; Guido M; Ciampelli M; Giuliani M; Leoni F; Perri C; Lanzone A Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448 [TBL] [Abstract][Full Text] [Related]
58. Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. Kent SC; Gnatuk CL; Kunselman AR; Demers LM; Lee PA; Legro RS J Clin Endocrinol Metab; 2008 May; 93(5):1662-9. PubMed ID: 18270257 [TBL] [Abstract][Full Text] [Related]
59. Abnormal response of insulin to glucose loading and assessment of insulin resistance in non-obese patients with polycystic ovary syndrome. Takeuchi T; Tsutsumi O; Taketani Y Gynecol Endocrinol; 2008 Jul; 24(7):385-91. PubMed ID: 18645711 [TBL] [Abstract][Full Text] [Related]
60. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Grulet H; Hecart AC; Delemer B; Gross A; Sulmont V; Leutenegger M; Caron J Clin Endocrinol (Oxf); 1993 Jun; 38(6):621-6. PubMed ID: 8334748 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]